Sponsor

Celgene Corporation

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Celgene Corporation appears in 73 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials73
Recruiting shown1
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

60 shown
Study of Nab-paclitaxel (Abraxane®) Treatment in Patients With Metastatic Breast Cancer in Routine Clinical PracticeNCT02655159 · lead sponsor · 2016-01-01
TERMINATED
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.NCT00319969 · lead sponsor · 2006-04-01
COMPLETED
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung CancerNCT00179699 · lead sponsor · 2005-09-01
TERMINATED
A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.NCT00179738 · lead sponsor · 2005-04-01
TERMINATED
Study of Adriamycin Plus Cyclophosphamide Followed by Abraxane as Adjuvant Therapy for Patients With Breast CancerNCT00107094 · lead sponsor · 2005-03-01
COMPLETED
A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung CancerNCT00179686 · lead sponsor · 2005-03-01
COMPLETED
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung CancerNCT00073723 · lead sponsor · 2003-12-01
COMPLETED
Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)NCT00072722 · lead sponsor · 2003-09-01
COMPLETED
ABI-007 in Taxol Resistant Patients With Metastatic Breast CancerNCT00046514 · lead sponsor · 2001-06-01
COMPLETED
Study of ABI-007 and Taxol in Patients With Metastatic Breast CancerNCT00046527 · lead sponsor · 2001-06-01
COMPLETED
Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting SyndromeNCT00002157 · lead sponsor
COMPLETED
Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast CancerNCT00380835 · lead sponsor
WITHDRAWN
A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting SyndromeNCT00002127 · lead sponsor
COMPLETED
Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma PatientsNCT02622581 · collaborator · 2015-12-01
RECRUITING
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)NCT06220201 · collaborator · 2024-03-28
ACTIVE_NOT_RECRUITING
Digital Gait Analysis in the Home Environment of Patients With Multiple SclerosisNCT04771858 · collaborator · 2021-03-09
COMPLETED
Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBCNCT03289819 · collaborator · 2018-03-23
COMPLETED
Denosumab as an add-on Neoadjuvant Treatment (GeparX)NCT02682693 · collaborator · 2017-02-13
COMPLETED
A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung CancerNCT02967133 · collaborator · 2016-12-01
TERMINATED
Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell CancerNCT02769832 · collaborator · 2016-08-29
COMPLETED
Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate CancerNCT02833883 · collaborator · 2016-07-01
COMPLETED
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLCNCT02716038 · collaborator · 2016-06-07
COMPLETED
Detect V / CHEVENDO (Chemo vs. Endo)NCT02344472 · collaborator · 2015-09-01
UNKNOWN
Albumin-Bound Paclitaxel and Gemcitabine in Patients With Untreated Stage IV or Recurrent Squamous Cell Lung CancersNCT02525653 · collaborator · 2015-08-01
COMPLETED
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)NCT02393794 · collaborator · 2015-07-17
ACTIVE_NOT_RECRUITING
Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLCNCT02382406 · collaborator · 2015-06-04
TERMINATED
Ph2 Nab-paclitaxel With Gemcitabine to Determine Efficacy in Advanced Non-squamous NSCLC.NCT02405910 · collaborator · 2015-03-15
WITHDRAWN
A Study of Carboplatin, Pemetrexed Plus Placebo vs Carboplatin, Pemetrexed Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With Non-Squamous Non-Small Cell Lung CancerNCT02259582 · collaborator · 2015-02-01
COMPLETED
Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung CancerNCT02018523 · collaborator · 2014-06-01
TERMINATED
Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast CancerNCT01938833 · collaborator · 2014-04-01
TERMINATED
Safety and Efficacy of Romidepsin and the Therapeutic Vaccine Vacc-4x for Reduction of the Latent HIV-1 ReservoirNCT02092116 · collaborator · 2014-03-01
COMPLETED
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With PaclitaxelNCT02073487 · collaborator · 2014-02-01
COMPLETED
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung CancerNCT01620190 · collaborator · 2012-12-02
COMPLETED
Vacc-4x + Lenalidomide vs. Vacc-4x +Placebo in HIV-1-infected Subjects on Antiretroviral Therapy (ART)NCT01704781 · collaborator · 2012-09-01
COMPLETED
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver DysfunctionNCT01638533 · collaborator · 2012-08-03
COMPLETED
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)NCT01583426 · collaborator · 2012-07-01
COMPLETED
Revlimid® as Consolidation Treatment Chronic Lymphocytic LeukemiaNCT01600053 · collaborator · 2011-11-01
TERMINATED
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast CancerNCT01207102 · collaborator · 2011-08-01
TERMINATED
Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid ArthritisNCT01261403 · collaborator · 2010-12-01
TERMINATED
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast CancerNCT01036087 · collaborator · 2010-11-01
COMPLETED
Concomitant Use of Apremilast for the Treatment of Active RA Despite TNF-Inhibition and Methotrexate- CATARANCT01204138 · collaborator · 2010-09-01
WITHDRAWN
Lenalidomide and Cetuximab in Patients With Advanced Solid TumorsNCT01166035 · collaborator · 2010-03-01
UNKNOWN
Lenalidomide and Paclitaxel in Prostate CancerNCT00933426 · collaborator · 2009-08-01
TERMINATED
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 ExpressionNCT00944047 · collaborator · 2009-07-01
COMPLETED
Amrubicin + Cyclophosphamide in Advanced Solid Organ MalignanciesNCT00890955 · collaborator · 2009-03-01
COMPLETED
Community Oncology Setting Cost Analysis and Disease Outcomes of Taxane Use in Metastatic Breast CancerNCT00876070 · collaborator · 2008-11-01
COMPLETED
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.NCT00777673 · collaborator · 2008-10-01
UNKNOWN
Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast CancerNCT01090128 · collaborator · 2008-09-01
TERMINATED
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast CancerNCT00748553 · collaborator · 2008-09-01
COMPLETED
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerNCT00729612 · collaborator · 2008-08-14
COMPLETED
Phase II NCT (Neoadjuvant Chemotherapy) w/ Weekly Abraxane in Combination With Carboplatin & Bevacizumab in Breast CancerNCT00675259 · collaborator · 2008-07-01
COMPLETED
Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung CancerNCT00642759 · collaborator · 2008-04-01
COMPLETED
Nanoparticle Albumin-Bound (Nab) Paclitaxel/Cyclophosphamide in Early-Stage Breast CancerNCT00629499 · collaborator · 2008-04-01
COMPLETED
Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC)NCT00903942 · collaborator · 2008-03-01
WITHDRAWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC PatientsNCT00654186 · collaborator · 2008-02-01
COMPLETED
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast CancerNCT00654836 · collaborator · 2007-10-01
COMPLETED
A Phase II Study Of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast CancerNCT00607438 · collaborator · 2007-09-01
TERMINATED
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate CancerNCT00521781 · collaborator · 2007-08-01
TERMINATED
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast CancerNCT00479674 · collaborator · 2007-05-01
COMPLETED
Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast CancerNCT00392392 · collaborator · 2006-10-01
COMPLETED

Drugs studied in this sponsor's trials

40 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Celgene Corporation as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
carboplatin12
Abraxane9
cyclophosphamide8
lenalidomide6
trastuzumab6
thalidomide5
bevacizumab4
epirubicin4
carboplatin RxCUI 40048 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 12 trials Abraxane RxCUI 589511 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 9 trials cyclophosphamide RxCUI 3002 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 8 trials lenalidomide RxCUI 342369 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 6 trials trastuzumab RxCUI 224905 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 6 trials thalidomide RxCUI 10432 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 5 trials bevacizumab RxCUI 253337 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 4 trials epirubicin RxCUI 3995 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 4 trials gemcitabine RxCUI 12574 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 4 trials paclitaxel RxCUI 56946 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 4 trials romidepsin RxCUI 877510 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 4 trials pertuzumab RxCUI 1298944 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials capecitabine RxCUI 194000 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials doxorubicin RxCUI 3639 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials nivolumab RxCUI 1597876 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials pemetrexed RxCUI 68446 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 2 trials Revlimid RxCUI 337535 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials anastrozole RxCUI 84857 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial apremilast RxCUI 1492727 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial bicalutamide RxCUI 83008 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cetuximab RxCUI 318341 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cisplatin RxCUI 2555 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial denosumab RxCUI 993449 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator60
lead sponsor13
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.